Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CYTH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.59
vs -0.34
Q1.23
N/A
-0.46
vs -0.33
Q2.23
N/A
-0.33
vs -0.41
Q3.23
N/A
-0.29
vs -0.50
Q4.23
N/A
-0.23
vs -0.59
Q1.24
N/A
-0.15
vs -0.46
Q2.24
N/A
-0.21
vs -0.33
Q3.24
N/A
-0.26
vs -0.29
Q4.24
N/A
-0.12
vs -0.23
Q1.25
N/A
-0.19
vs -0.15
Sales Growth
YoY
Current
Estimates
Q4.22
-68%
186.8K vs 585.1K
Q1.23
-22%
152.4K vs 194.9K
Q2.23
-78%
117.1K vs 541.9K
Q3.23
+10%
495.5K vs 452.2K
Q4.23
+67%
311.4K vs 186.8K
Q1.24
+33%
202.4K vs 152.4K
Q2.24
+5%
123.1K vs 117.1K
Q3.24
-53%
233.8K vs 495.5K
Q4.24
+74%
543K vs 311.4K
Q1.25
-1%
200K vs 202.4K
Return on Equity
QoQ
Q4.22
-655%
-6.55
vs -0.76
Q1.23
+1141%
11.41
vs -6.55
Q2.23
+312%
3.12
vs 11.41
Q3.23
+453%
4.53
vs 3.12
Q4.23
-119%
-1.19
vs 4.53
Q1.24
-712%
-7.12
vs -1.19
Q2.24
+117%
1.17
vs -7.12
Q3.24
+66%
0.66
vs 1.17
Institutionnal Ownership
QoQ
Q1.23
16
16
vs 14
14%
Q2.23
14
14
vs 16
-12%
Q3.23
17
17
vs 14
21%
Q4.23
21
21
vs 17
24%
Q1.24
22
22
vs 21
5%
Q2.24
21
21
vs 22
-5%
Q3.24
18
18
vs 21
-14%
Q4.24
20
20
vs 18
11%
zacks.com
8 hours ago
Quote Panel
Key Metrics
Forecast
671%2025-Revenue
-61%2025-EPS
78%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
H.C. Wainwright
downgradePrevious: Not converted
2024-08-23
Now: Neutral
Morgan Stanley
downgradePrevious: Not converted
2023-09-27
Now: Underweight
Maxim Group
upgradePrevious: Not converted
2023-09-27
Now: Buy
Bernstein
initialisePrevious: Not converted
2023-03-21
Now: Market Perform
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
NASDAQ
Unprofitable
Unprofitable
Relative Strenght
36
Volume Buzz
-89%
Earning Acce
No
Dist 52w H.
56%Relative Strength
CYTH
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
